Efficacy and safety of paliperidone palmitate 3-month versus 1-month formulation in patients with schizophrenia: comparison between European and non-European population

MLA

Savitz, Adam J., et al. “Efficacy and Safety of Paliperidone Palmitate 3-Month versus 1-Month Formulation in Patients with Schizophrenia: Comparison between European and Non-European Population.” Neuropsychiatric Disease & Treatment, vol. 15, Feb. 2019, pp. 587–602. EBSCOhost, https://doi.org/10.2147/NDT.S189668.

APA

Savitz, A. J., Xu, H., Gopal, S., Nuamah, I., Ravenstijn, P., Hough, D., & Hargarter, L. (2019). Efficacy and safety of paliperidone palmitate 3-month versus 1-month formulation in patients with schizophrenia: comparison between European and non-European population. Neuropsychiatric Disease & Treatment, 15, 587–602. https://doi.org/10.2147/NDT.S189668

Chicago

Savitz, Adam J, Haiyan Xu, Srihari Gopal, Isaac Nuamah, Paulien Ravenstijn, David Hough, and Ludger Hargarter. 2019. “Efficacy and Safety of Paliperidone Palmitate 3-Month versus 1-Month Formulation in Patients with Schizophrenia: Comparison between European and Non-European Population.” Neuropsychiatric Disease & Treatment 15 (February): 587–602. doi:10.2147/NDT.S189668.